Thymosin Alpha-1: Research Overview, Mechanisms, and Current Evidence
Thymosin alpha-1 (Ta1, thymalfasin) is a 28-amino-acid peptide naturally produced by the thymus gland and long studied for its immune-modulating activity. It is marketed in several countries as the prescription drug thymalfasin (Zadaxin) but is not approved by the US FDA. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
In preclinical and clinical research, thymosin alpha-1 has been reported to modulate immune cell function, acting in part through Toll-like receptor signaling.
- Reported to promote maturation and differentiation of T cells and to influence dendritic cell function.
- Studied as a signal through Toll-like receptors (including TLR7 and TLR9) that shapes innate and adaptive immune responses.
- Investigated for restoring immune balance in conditions marked by both excessive inflammation and immune suppression.
- Reported to reduce markers of T-cell exhaustion and to support effector T-cell activity in experimental settings.
Areas of Research Interest
Published studies have examined thymosin alpha-1 in the following research contexts, ranging from cell models to randomized clinical trials.
Sepsis and critical illness
Studied in randomized trials as an adjunctive immunomodulator in severe sepsis and critically ill patients.
Viral infection
Investigated in hepatitis B and in cohort studies of critically ill COVID-19 patients for immune support.
Cancer immunity
Examined in preclinical models as a way to enhance antitumor immune responses alongside chemotherapy and immunotherapy.
T-cell function
Studied in cell models for effects on T-cell activation, cytokine production, and reversal of exhaustion markers.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in specific published studies, with sources. It describes what researchers administered in these models and is not a protocol, recommendation, or guidance for use in humans or animals. Animal-study doses are expressed per kilogram of body weight.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Critically ill COVID-19 patients (cohort study) | 1.6 mg once daily or every 12 hours, subcutaneous, for more than 5 days | Wu 2020·DOI |
| Severe sepsis (randomized controlled trial) | Subcutaneous thymosin alpha-1 as adjunctive therapy; 28-day mortality endpoint | Wu 2013·DOI |
| Human research (regulatory status) | Marketed as prescription thymalfasin (Zadaxin) in several countries; not approved by the US FDA | Dominari 2020·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2020 to 2026)
Recent peer-reviewed literature indexed on PubMed continues to characterize how thymosin alpha-1 modulates immunity across infection, critical illness, and cancer models.
Antitumor immunity after chemotherapy (mouse)
A 2026 study reported that thymosin alpha-1 restored chemotherapy-impaired antitumor immunity in mice by protecting a microRNA that activates TLR7 in dendritic cells, helping license tumor-specific CD8 T-cell responses. PubMed·DOI
T-cell activation and exhaustion (in vitro)
A 2026 study reported that thymosin alpha-1 enhanced activation of human CD8 T-cells and reduced exhaustion markers such as PD-1, TIM-3, and LAG-3 after chronic stimulation, suggesting a supportive role in T-cell-based research. PubMed·DOI
Hepatitis B liver failure (randomized trial)
A 2026 randomized controlled trial in patients with hepatitis B-related acute-on-chronic liver failure reported that adding thymosin alpha-1 to standard therapy improved 90-day transplant-free survival and helped rebalance the immune response. PubMed·DOI
Critically ill COVID-19 (cohort)
A 2020 multicenter retrospective cohort study reported that thymosin alpha-1, given at 1.6 mg once daily or every 12 hours, was associated with lower 28-day mortality in critically ill COVID-19 patients, with benefit concentrated in those with marked lymphopenia. PubMed·DOI
Research Questions
What is thymosin alpha-1?
Thymosin alpha-1 is a 28-amino-acid peptide naturally produced by the thymus that has been studied for decades as an immune modulator, and is marketed as the prescription drug thymalfasin in some countries.
What is the current state of human evidence?
Human research includes randomized trials in severe sepsis and hepatitis B liver failure and cohort studies in COVID-19. Findings are promising in some settings but not uniform, and it is not FDA-approved.
What does the available safety literature suggest?
Clinical studies have generally reported good tolerability with no serious drug-related adverse events, but its regulatory status varies by country and it should be treated as investigational for research purposes here.
Referenced Citations
Literature indexed on PubMed.
- Wei, Y., et al. (2026). Thymosin alpha-1 restores chemotherapy-induced antitumor immunity by chaperoning a microRNA ligand of TLR7 in dendritic cells. Cancer Res. PubMed·DOI
- Mishra, S., et al. (2026). Thymosin alpha-1 augments CD8+ T-cell activation and reverses exhaustion in vitro. Asian Pac. J. Cancer Prev., 27(6), 2089-2096. PubMed·DOI
- Li, Z.H., et al. (2026). Thymosin alpha-1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance. Immunopharmacol. Immunotoxicol., 48(2), 341-353. PubMed·DOI
- Wu, M., et al. (2020). Thymosin alpha-1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. Int. Immunopharmacol., 88, 106873. PubMed·DOI
- Wu, J., et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care, 17(1), R8. PubMed·DOI
- Dominari, A., et al. (2020). Thymosin alpha 1: A comprehensive review of the literature. World J. Virol., 9(5), 67-78. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.